Exact Sciences (EXAS) EBIAT (2016 - 2025)
Exact Sciences (EXAS) has disclosed EBIAT for 16 consecutive years, with -$86.0 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 90.06% to -$86.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$207.9 million, a 79.79% increase, with the full-year FY2025 number at -$207.9 million, up 79.79% from a year prior.
- EBIAT was -$86.0 million for Q4 2025 at Exact Sciences, down from -$19.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $794000.0 in Q3 2023 to a low of -$864.6 million in Q4 2024.
- A 5-year average of -$133.0 million and a median of -$93.6 million in 2025 define the central range for EBIAT.
- Peak YoY movement for EBIAT: skyrocketed 100.53% in 2023, then crashed 4915.62% in 2024.
- Exact Sciences' EBIAT stood at -$220.6 million in 2021, then surged by 42.09% to -$127.7 million in 2022, then skyrocketed by 61.04% to -$49.8 million in 2023, then plummeted by 1637.3% to -$864.6 million in 2024, then surged by 90.06% to -$86.0 million in 2025.
- Per Business Quant, the three most recent readings for EXAS's EBIAT are -$86.0 million (Q4 2025), -$19.6 million (Q3 2025), and -$1.2 million (Q2 2025).